

Gene Expression Profiling in Human High-Grade Astrocytomas

Zhongyu Liu,¹ Zhiqiang Yao,² Chao Li,³ Yicheng Lu,^{*4} and Chunfang Gao^{*1}

1 Anal-Colorectal Surgery Institute, No. 150 Central Hospital of PLA, Luoyang, Henan 471031, China

2 Department of Neurosurgery, No. 150 Central Hospital of PLA, Luoyang, Henan 471031, China


3 Division of Head and Neck Surgery, Sichuan Cancer Hospital, Chengdu 610041, China

4 Changzheng Hospital, Second Military Medical University, Shanghai 200003, China

*Correspondence should be addressed to Chunfang Gao and Yicheng Lu, gaochunfang2010@163.com


This PDF file includes:
 Supplementary Figure 1
 Supplementary Figure 2
 Supplementary Table 1
 Supplementary Table 2

Figures and legends



Supplementary Figure 1: The quality control status map. Quality control plot for all arrays. A: Quality control statistic plot. Different chips are separated by horizontal grey dotted lines in the plot. The red numbers on the left report the number of probe sets with present flag, and the average background on the chip. The blue region in the middle denotes the area where scaling factors are less than 3-fold of the mean scale factors of all chips. Bars that end with a point denote scaling factor for the chips. The triangles denote beta-actin 3': 5' ratio, and open circles are GAPDH 3': 5' ratios. If the scaling factors or ratios fall within the 3-fold region (1.25-fold for GAPDH), they are colored blue, otherwise red. The deviant chips are therefore easy to pick of by their red coloring; B: RNA degradation plot: In the resulting image every single array is

represented by one line. The idea is to check whether the slopes and profiles of the lines are similar for all arrays.



Supplementary Figure 2: ACMs classification: Training error plot and misclassification errors are shown as a function of the threshold parameter τ . The value τ (threshold)=41.0 is chosen and yields a subset of 171 selected genes, including the 132 genes referred to as normal tissue markers.

Tables and legends

Supplementary Table 1: significant overrepresented GO terms for the set of differentially expressed genes of ACM tissue. 2649 differentially expressional genes were analyzed using DAVID system (parameter settings, refer to Methods and Materials) (<http://david.abcc.ncifcrf.gov/>). The significantly over-represented GO terms (FDR< 0.5 and Number of genes within a single pathway >10) are identified.

| GO Ontology | Term | Count | FDR |
|--------------------|---------------------------------------------------------|-------|----------|
| | GO:0007242~intracellular signaling cascade | 197 | 0.018959 |
| biological process | GO:0043065~positive regulation of apoptosis | 79 | 0.0973 |
| | GO:0043068~positive regulation of programmed cell death | 79 | 0.124233 |

| | | |
|--------------------------------------------------------------|-----|----------|
| G0:0010942~positive regulation of cell death | 79 | 0.145894 |
| G0:0016568~chromatin modification | 54 | 0.295214 |
| G0:0008219~cell death | 117 | 0.352727 |
| G0:0007010~cytoskeleton organization | 77 | 0.451875 |
| G0:0016265~death | 117 | 0.461443 |
| G0:0015674~di-, tri-valent inorganic cation transport | 38 | 0.526657 |
| G0:0008104~protein localization | 138 | 0.534804 |
| G0:0006816~calcium ion transport | 32 | 0.80372 |
| G0:0006350~transcription | 294 | 0.894109 |
| G0:0042981~regulation of apoptosis | 126 | 0.952536 |
| G0:0010627~regulation of protein kinase cascade | 48 | 1.184242 |
| G0:0000165~MAPKKK cascade | 38 | 1.28682 |
| G0:0043067~regulation of programmed cell death | 126 | 1.404968 |
| G0:0010941~regulation of cell death | 126 | 1.610926 |
| G0:0007254~JNK cascade | 17 | 1.769651 |
| G0:0033500~carbohydrate homeostasis | 15 | 2.074711 |
| G0:0042593~glucose homeostasis | 15 | 2.074711 |
| G0:0045184~establishment of protein localization | 119 | 2.203149 |
| G0:0015031~protein transport | 118 | 2.248817 |
| G0:0006917~induction of apoptosis | 57 | 2.546204 |
| G0:0007243~protein kinase cascade | 64 | 2.656027 |
| G0:0012502~induction of programmed cell death | 57 | 2.738234 |
| G0:0033554~cellular response to stress | 91 | 2.808061 |
| G0:0012501~programmed cell death | 97 | 2.915256 |
| G0:0006468~protein amino acid phosphorylation | 104 | 3.515993 |
| G0:0031098~stress-activated protein kinase signaling pathway | 17 | 3.721198 |
| G0:0006915~apoptosis | 95 | 4.027922 |
| G0:0051276~chromosome organization | 79 | 4.088372 |

| | | | | |
|-----------------------|------------------------------------------------------|-------|----------|--|
| | G0:0030155~regulation of cell adhesion | 29 | 4.183801 | |
| | G0:0045930~negative regulation of mitotic cell cycle | 9 | 4.519829 | |
| | G0:0033674~positive regulation of kinase activity | 43 | 4.602038 | |
| | G0:0007162~negative regulation of cell adhesion | 13 | 5.611682 | |
| | G0:0007162~negative regulation of cell adhesion | 13 | 5.611682 | |
| | ----- | | | |
| | G0:0019898~extrinsic to membrane | 93 | 0.001248 | |
| | G0:0012505~endomembrane system | 129 | 0.01277 | |
| | G0:0030054~cell junction | 91 | 0.030208 | |
| | G0:0031981~nuclear lumen | 211 | 0.091487 | |
| | G0:0016585~chromatin remodeling complex | 21 | 0.121437 | |
| | G0:0044456~synapse part | 49 | 0.16497 | |
| | G0:0005654~nucleoplasm | 136 | 0.185168 | |
| | G0:0016605~PML body | 13 | 0.231965 | |
| | G0:0031300~intrinsic to organelle membrane | 33 | 0.256589 | |
| | G0:0045202~synapse | 64 | 0.282216 | |
| Cellular Component | G0:0031301~integral to organelle membrane | 29 | 0.327755 | |
| | G0:0044459~plasma membrane part | 299 | 0.407759 | |
| | G0:0000118~histone deacetylase complex | 14 | 0.596212 | |
| | G0:0031090~organelle membrane | 160 | 0.705946 | |
| | G0:0005626~insoluble fraction | 126 | 1.038663 | |
| | G0:0005624~membrane fraction | 122 | 1.092698 | |
| | G0:0034703~cation channel complex | 29 | 1.099605 | |
| | G0:0048471~perinuclear region of cytoplasm | 52 | 1.159989 | |
| | G0:0044451~nucleoplasm part | 88 | 1.463588 | |
| | G0:0005856~cytoskeleton | 193 | 1.671759 | |
| | G0:0008021~synaptic vesicle | 19 | 2.548427 | |
| | G0:0005794~Golgi apparatus | 127 | 3.149324 | |
| | | ----- | | |

| | | | |
|--------------------|---------------------------------------------------------|-----|----------|
| | G0:0015630~microtubule cytoskeleton | 85 | 3.561803 |
| | G0:0070013~intracellular organelle lumen | 238 | 4.426508 |
| | G0:0042995~cell projection | 103 | 5.456561 |
| | G0:0019899~enzyme binding | 102 | 6.27E-04 |
| | G0:0046872~metal ion binding | 571 | 0.006589 |
| | G0:0043169~cation binding | 572 | 0.017693 |
| | G0:0043167~ion binding | 578 | 0.02774 |
| | G0:0051020~GTPase binding | 30 | 0.031498 |
| | G0:0008270~zinc ion binding | 334 | 0.046106 |
| | G0:0031267~small GTPase binding | 28 | 0.054999 |
| | G0:0017016~Ras GTPase binding | 25 | 0.185784 |
| | G0:0005085~guanyl-nucleotide exchange factor activity | 34 | 0.648109 |
| | G0:0046873~metal ion transmembrane transporter activity | 61 | 0.658748 |
| Molecular Function | G0:0046914~transition metal ion binding | 384 | 0.684135 |
| | G0:0008092~cytoskeletal protein binding | 85 | 1.213221 |
| | G0:0008134~transcription factor binding | 86 | 1.358523 |
| | G0:0019904~protein domain specific binding | 60 | 1.425775 |
| | G0:0030695~GTPase regulator activity | 70 | 1.808413 |
| | G0:0016563~transcription activator activity | 70 | 2.672279 |
| | G0:0060589~nucleoside-triphosphatase regulator activity | 70 | 3.241935 |
| | G0:0022843~voltage-gated cation channel activity | 31 | 3.243998 |
| | G0:0005083~small GTPase regulator activity | 50 | 3.456746 |
| | G0:0004674~protein serine/threonine kinase activity | 71 | 5.755474 |

Supplementary Table 2: Dys-regulated pathways (p-values<0.01) associated with ACM were identified by DAVID.

| Category | Term | Count | % | PValue |
|--------------|------------------------------------------------|-------|------|----------|
| | hsa04010:MAPK signaling pathway | 47 | 2.01 | 0.001037 |
| | hsa00562:Inositol phosphate metabolism | 16 | 0.68 | 0.001055 |
| | hsa05414:Dilated cardiomyopathy | 21 | 0.9 | 0.00447 |
| | hsa04070:Phosphatidylinositol signaling system | 18 | 0.77 | 0.004708 |
| | hsa04510:Focal adhesion | 37 | 1.58 | 0.006156 |
| | hsa04020:Calcium signaling pathway | 33 | 1.41 | 0.007611 |
| | hsa05215:Prostate cancer | 19 | 0.81 | 0.014472 |
| | hsa05216:Thyroid cancer | 9 | 0.38 | 0.016108 |
| | hsa05222:Small cell lung cancer | 18 | 0.77 | 0.017088 |
| | hsa05212:Pancreatic cancer | 16 | 0.68 | 0.018884 |
| | hsa05223:Non-small cell lung cancer | 13 | 0.56 | 0.021032 |
| | hsa04210:Apoptosis | 18 | 0.77 | 0.02368 |
| | hsa00604:Glycosphingolipid biosynthesis | 6 | 0.26 | 0.024603 |
| | hsa04660:T cell receptor signaling pathway | 21 | 0.9 | 0.025853 |
| KEGG_PATHWAY | hsa04810:Regulation of actin cytoskeleton | 36 | 1.54 | 0.028 |
| | hsa05221:Acute myeloid leukemia | 13 | 0.56 | 0.035388 |
| | hsa05014:Amyotrophic lateral sclerosis (ALS) | 12 | 0.51 | 0.042056 |
| | hsa04666:Fc gamma R-mediated phagocytosis | 18 | 0.77 | 0.050519 |
| | hsa05220:Chronic myeloid leukemia | 15 | 0.64 | 0.053181 |
| | hsa05211:Renal cell carcinoma | 14 | 0.6 | 0.063137 |
| | hsa04520:Adherens junction | 15 | 0.64 | 0.06407 |
| | hsa04912:GnRH signaling pathway | 18 | 0.77 | 0.064667 |
| | hsa00310:Lysine degradation | 10 | 0.43 | 0.067665 |
| | hsa05410:Hypertrophic cardiomyopathy (HCM) | 16 | 0.68 | 0.070304 |
| | hsa04360:Axon guidance | 22 | 0.94 | 0.076563 |
| | hsa04150:mTOR signaling pathway | 11 | 0.47 | 0.079271 |
| | hsa05213:Endometrial cancer | 11 | 0.47 | 0.079271 |

| | | | | |
|----------|---------------------------------------------------------------------------------------------------|----|------|----------|
| | hsa04620:Toll-like receptor signaling pathway | 18 | 0.77 | 0.081297 |
| | h_ctcfPathway:CTCF: First Multivalent Nuclear Factor | 7 | 0.3 | 0.041372 |
| | h_fasPathway:FAS signaling pathway (CD95) | 9 | 0.38 | 0.046127 |
| | h_p38mapkPathway:p38 MAPK Signaling Pathway | 9 | 0.38 | 0.064165 |
| BIOCARTA | h_hdacPathway:Control of skeletal myogenesis by HDAC & calcium/calmodulin-dependent kinase (CaMK) | 6 | 0.26 | 0.066071 |
| | h_atrbrcaPathway:Role of BRCA1, BRCA2 and ATR in Cancer Susceptibility | 7 | 0.3 | 0.076547 |
| | h_bard1Pathway:BRCA1-dependent Ub-ligase activity | 4 | 0.17 | 0.079928 |
| | h_arfPathway:Tumor Suppressor Arf Inhibits Ribosomal Biogenesis | 5 | 0.21 | 0.084664 |